Femasys Inc.
Femasys Inc. scores highest on Earnings (34) and lowest on Torque (12). Its PosiPenta is 20.59 out of 100, weaker than most similar companies.
On the Penta Grid this week, Femasys Inc. is Grid #828 of 837 in the Healthcare sector in United States, and Grid #3,925 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Femasys Inc. | 20.59 | 19 | 34 | 12 | 12 | 26 |
| Tvardi Therapeutics, Inc. | 35.02 | 32 | 31 | 17 | 46 | 49 |
| Cerenome, Inc. | 28.31 | 25 | 31 | 14 | 41 | 30 |
| Daré Bioscience, Inc. | 27.26 | 0 | 53 | 18 | 19 | 46 |
| IRIDEX Corporation | 44.62 | 17 | 75 | 47 | 27 | 57 |
| Allarity Therapeutics, Inc. | 28.90 | 17 | 37 | 43 | 12 | 37 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -0.50 |
| P/B ratio | 3.43 |
EEarnings
| Trailing EPS | ₹-310.67 |
| Forward EPS | ₹-201.27 |
NNitro
| Price | 156.28 |
| 52-week high | 2102.67 |
| 52-week low | 138.28 |
| Fall from 52-week high | 92.6% |
TTorque
| Return on equity (ROE) | -424.97% |
| Debt-to-equity | 1.19 |
AAnchor
| Beta (price swings) | -2.15 |
| Market cap | ₹130 Cr |
| Insider holding | 3.92% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Femasys Inc.'s PosiPenta score?
Femasys Inc.'s PosiPenta is 20.59 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Femasys Inc. stand on the Penta Grid?
On the Penta Grid this week, Femasys Inc. is Grid #828 of 837 in the Healthcare sector in United States, and Grid #3,925 of 4,000 in United States.
Which PosiPenta pillar is strongest for Femasys Inc.?
Earnings (growth), with a score of 34 out of 100: weaker than most similar companies.
Which PosiPenta pillar is weakest for Femasys Inc.?
Torque (durability), with a score of 12 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.